The global raloxifene hydrochloride tablets market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). These tablets are generally recommended as preventative medicine for osteoporosis as well as a treatment medicine for breast cancer. It can also be taken orally for prevention or treatment of bone loss caused by hormone therapy, which occurs due to a lack of estrogen after menopause. Thus, the growing prevalence of breast cancer and osteoporosis especially among older women is anticipated to spur market growth. Further, the properties of raloxifene hydrochloride such as prevention of flashes, vaginal dryness, night sweats, along with the reduction of chances for cardiac arrest & stroke is also largely contributing to the market growth.
In terms of geography, Europe is anticipated to register substantial growth. The primary factors attributing to this growth include the rising population base suffering from osteoporosis and other bone disorders, growing healthcare expenditure and so on. However, a lack of awareness among rural people will hinder the growth of the global raloxifene hydrochloride market. Although some leading players offer combination therapies along with their products which are expected to propel demand during the next few years.
Market Coverage
Competitive Landscape: Eli Lilly and Company, InvaGen Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Raloxifene Hydrochloride Tablets Market Report by Segment
By Application
• Osteoporosis
• Breast Cancer
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Raloxifene Hydrochloride Tablets Market by Region
North America
Europe
Asia-Pacific
Rest of the World